SEARCH BY
| Category | Company |
|---|---|
| Founded | 1980 |
| Sector | Life Science |
| Employees | 28,000 |
| Revenue | 33.4B USD (2024) |
Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 21 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 9 of 20 |
| Country: Brazil M&A | 1 of 1 |
| Year: 2011 M&A | 2 of 2 |
| Size (of disclosed) | 19 of 20 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-01-24 |
BioVex Group
Woburn, Massachusetts, United States BioVex Group, Inc. is a biotechnology company based in Woburn, Mass., with additional operations in Abingdon, UK. BioVex produces OncoVEX(GM-CSF), a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. |
Buy | $1.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-01-26 |
Micromet
Rockville, Maryland, United States Micromet, Inc. is a biopharmaceutical company, engages in the discovery, development, and commercialization of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE antibody platform, as well as conventional monoclonal antibodies. |
Buy | $1.2B |
